Combination immunotherapy of cancer

NeuroImmune Biology

Volumn 1, Issue C, 2001, Pages 417-432

  E, Nagy ^a   I, Berczi ^a   E, Baral ^b   Kellen, J ^c  

^a UNIVERSITY OF MANITOBA   (Canada)

^b CANCERCARE MANITOBA   (Canada)

^c SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77957800234     PISSN: 15677443     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1567-7443(01)80039-9     Document Type: Article

References (72)

1. National Cancer Institute of Canada. Canadian cancer statistics (1999), The National Cancer Institute, Toronto
2. Grover S.A., Coupal L.C., Zowall H., and Goldenberg L. The economic burden of prostate cancer in Canada: Forecasts from the Montreal Prostate Cancer Model. CMAJ 162 (2000) 977
3. Klein G., Sjogren H.O., Klein E., and Hellstrom K.E. Demonstration of resistance against methylcholantrene-induced sarcomas in the primary autochthonous host. Cancer Res 20 (1960) 1561
4. Berczi I., Strausbauch P., and Sehon A.H. Rejection of tumor cells in vitro. Science 180 (1973) 1289
5. Berczi I., and Sehon A.H. Effector and suppressor lymphoid cells in tumor bearing guinea pigs. Int J Cancer 23 (1979) 274
6. Mule J.J., Hellstrom I., and Hellstrom K.E. Cell surface phenotypes of radiolabelled immune long-lived lymphocytes that selectively localize in syngeneic tumors. Am J Pathol 107 (1982) 142
7. Austin F.C., Finerty J.F., and Sogn J.A. Cancer immunology: highlight of the NCI extramural immunology program. Cancer Invest 8 (1990) 207
8. Hellstrom I., and Hellstrom K.E. Tumor immunology: an overview. Ann NY Acad Sci 690 (1993) 24
9. Yamaguchi A., Taga K., Mostowski H.S., and Bloom E.T. Target cell induced apoptosis of interleukin-2 activated human natural killer cells: Roles of cell surface molecules and intracellular events. Blood 87 (1996) 5127
10. Vivier E., Morin P., O'Brien C., Druker B., Schlossman F.S., and Anderson P. Tyrosine phosphorylation of the Fc gamma R III (CD16): Zeta complex in human natural killer cells. Induction by antibody dependent cytotoxicity butnot by natural killing. J Immunol 146 (1991) 206
11. Welsh R.M. Regulation of virus infections by natural killer cells: a review. Nat Immun Cell Growth Regul 5 (1986) 169
12. Maghazachi A.A., Vujanovic N.L., Herberman R.B., and Miserodt J.C. Lymphokine activated killer cells in rats, IV: developmental relationships among large agranular lymphocytes, large granular lymphocytes and lymphokine activated killer cells. J Immunol 140 (1988) 2846
13. Sarin A., Adler W.H., and Saxena R.K. Lack of optimal activation of natural killer levels by interleukin-2 in rat spleen cells: evidence of suppression. Cell Immunol 122 (1989) 548
14. Cho D., Lee W.J., Halloran P.J., Trinchieri G., and Kim T.B. Enhancement of porcine natural killer cell activity by recombinant human and murine IL-2. Cell Immunol 172 (1996) 29
15. T. Dao T., Mehal W.Z., and Crispe I.N. IL-18 augments perforin dependent cytotoxicity of liver NK-T Cells. J Immunol 161 (1998) 2217
16. Herrera C., Garcia-Perez M.J., Ramirez R., Martin C., Alvarez M.A., Martinez F., Gomez P., Garcia-Castellano J.M., and Torres A. Lymphokine activated killer (LAK) cell generation from peripheral blood stem cells by in vitro incubation withd low-dose interleukin-2 plusgranulocyte-macrophage colony-stimulating factor. Bone Marrow Transpl 19 (1997) 545
17. LaFever A.V., Piaskowski V.D., Casper J.T., and Truitt R.L. Kinetic analysis of human IL-2 activated cytotoxic cells. Immuno Pharmacol Immunotoxicol 13 (1991) 147
18. Rosenberg S.A., Lotze M.T., Muul L.M., Leitman S., Chang A.E., Avis F.P., and Leitman S. A progress report of 157 patients with advanced cancer using lymphokine activated killer cells and interleukin-2 or high dose interleukin-2 alone. New Engl J Med 316 (1987) 889
19. Rosenberg S.A., Lotze M.T., Muul L.M., Leitman S., Chang A.E., and Ettinghausen S.E. Observation on the systemic administration of autologous lymphokine activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. New Engl J Med 313 (1985) 1485
20. El-Khatib M., Stanger Z., Dogan H., Cui H., and Ju S. The molecular mechanism of FasLmediated cytotoxicity by CD4+ Th1 clones. Cell Immunol 163 (1995) 237
21. Russel J.H. Internal disintegration model of cytotoxic lymphocytes induced target damage. Immunol Rev 72 (1983) 97
22. Zychlinsky A., Zheng L.M., Liu C., and Young J.D. Cytolytic lymphocytes induce both apoptosis and necrosis in target cells. J Immunol 146 (1991) 393
23. Kallio S., Kangas L., Blanco G., Johansson R., Karjalainen A., Perila M., Pippo I., Sundquist H., Sodervall M., and Toivola R. A new triphenylethylene compound, Fc-1157a. Hormonal effects. Cancer Chemother Pharmacol 17 (1986) 103
24. Kangas L., Nieminen A.L., Blanco G., Gronroos M., Kallio S., Karjalainen A., Perila M., Sodervall M., and Toivola R. A new triphenylethylene compound, Fc-1157A. Antitumor effects. Cancer Chemother Pharmacol 17 (1986) 109
25. Lerner L.J., and Jordan V.C. Development of antiestrogens and their use in breast cancer: 8th Cain memorial award lecture. Cancer Res 50 (1990) 4177
26. Paavonen T., and Anderson L.C. The estrogen antagonists, tamoxifen and Fc1157a, display estrogen like effects on human lymphocyte function in vitro. Clin Exp Immunol 61 (1985) 467
27. Valavaara R., and Touminen J.A.T. The immunological status of breast cancer patients during treatment with a new antiestrogen, toremifene. Cancer Immunol Immunother 31 (1990) 381
28. Baral E., Nagy E., and Berczi I. The effect of tamoxifen on the immune response. In: Kellen J.A. (Ed). Tamoxifen: Beyond the antiestrogens (1996), Birkhauser, Boston 137-178
29. Baral E., Glas U., Rutquist L.E., and Skoog L. Adjuvant therapy in postmenopausal patients with operable breast cancer. Fundamental Problems in Breast Cancer (1987), M Nijhoff, Amsterdam 335
30. Warri A., and Kangas L. Effect of toremifene on the activity of NK-cells in NZB/NZW mice. J Steroid Biochem 36 (1990) 207
31. Rotstein S., Blomgren H., Petrini B., Wasserman J., and Von Stedingk V.L. Influence of adjuvant tamoxifen on blood lymphocytes. Breast Cancer Res Treat 12 (1988) 75
32. G. Berry G., Green B.J., and Matheson D.S. Modulation of natural killer cell activity by tamoxifen in stage I post-menopausal breast cancer. Eur J Cancer Clin Oncol 23 (1987) 517
33. Mandeville R., Galli S.S., and Chausseau J.P. In vitro stimulation of human NK activity by an estrogen antagonist (tamoxifen). Eur J Cancer Clin Oncol 20 (1984) 983
34. Baral E., and Vanky F. Effect of tamoxifen on the cell-mediated auto tumor lysis. J Clin Lab Immunol 22 (1987) 97
35. Baral E., Nagy E., and Berczi I. Modulation of natural killer cell-mediated cytotoxicity by tamoxifen and estradiol. Cancer 75 (1995) 591
36. Baral E., Nagy E., and Berczi I. Modulation of lymphokine-activated killer cell-mediated cytotoxicity by estradiol and tamoxifen. Int. J Cancer 66 (1996) 214
37. Albertini M.R., Gibson D.F.C., Robinson S.P., Howard S.P., Tans K.J., Lindstrom M.J., Robinson R.R., Tormey D.C., Jordan V.C., and Sondel P.M. Influence of estradiol and tamoxifen on susceptibility of human breast cancer cell lines to lysis by lymphokine activated killer cells. J Immunother 11 (1992) 30
38. Baral E., Nagy E., and Berczi I. Target cells are sensitized for cytotoxic T-lymphocytes-mediated destruction by estradiol and tamoxifen. Int J Cancer 58 (1994) 64
39. Baral E., Nagy E., Kangas L., and Berczi I. Immunotherapy of the SL2-5 murine lymphoma with natural killer cells and tamoxifen or tornemifene. Anticancer Res 17 (1997) 77
40. Lafneiere R., and Rosenberg S.A. Successful immunotherapy of murine experimental hepatic metastases with lymphokine activated killer cells and recombinant interleukin-2. Cancer Res 45 (1985) 3735
41. Rosenberg S.A., Mule J.J., Spiess P.J., Reicher C.M., and Schwartz S.L. Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high dose recombinant interleukin-2. J Exp Med 161 (1985) 1169
42. Kim B., Varnaka P., and Konrad C. Tamoxifen potentiates in vivo antitumor activity of interleukin-2. Surgery 108 (1990) 139
43. Baral E., Nagy E., and Berczi I. Anti-estrogens enhance the therapeutic effect of lymphokine-activated killer cells on the P815 murine mastocytoma. Int J Cancer 67 (1996) 580
44. Ioannides C.G., Platsoucas C.D., Rashed S., Wharton T.J., Edwards C.L., and Freedman R.S. Tumor cytolysis by lymphocytes infiltrating ovarian malignant ascites. Cancer Res 51 (1991) 4257
45. Nagy E., Baral E., Kangas L., and Berczi I. Anti-estrogens potentiate the immunotherapy of the P815 murine mastocytoma by cytotoxic T lymphocytes. Anticancer Res 17 (1997) 1083
46. Topalian S.L., Muul L.M., Solomon D., and Rosenberg S.A. Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials. J Immunol Methods 102 (1987) 127
47. Ioannides C.G., Freedman R.S., Platsoucas C.D., Rashed S., and Kim Y.P. Cytotoxic T cell clones isolated from ovarian tumor infiltrating lymphocytes recognize multiple antigenic epitopes on autologous tumor cells. J Immunol 146 (1991) 1700
48. Ioannides C.G., Fisk B., Jerome K., Irimura T., Wharton J.T., and Finn O.J. Cytotoxic T cells from ovariant malignant tumors can recognize polymorphic epithelial mucin core peptides. J Immunol 151 (1993) 3693
49. Vaccarello L., Y. Wang Y., and Witeside T.L. Sustained outgrowth of auto-tumor reactive T lymphocytes from human ovarian carcinomas in the presence of tumor necrosis factor and IL-2. Hum Immunol 28 (1990) 216
50. Kimura H., Yamaguchi Y., and Fujisawa T. Cytotoxicity of autologous and allogeneic lymphocytes against cultured human lung cancer cells: optimal conditions for the production of cytotoxic lymphocytes. Gann 75 (1984) 1006
51. Kurnick J.T., Kradin R.L., Blumberg R., Schneeberger E.E., and Boyle L.A. Functional characterization of T lymphocytes propagated from human lung carcinomas. Clin Immunol Immunopathol 38 (1986) 367
52. Baral E., Nagy E., Krepart G.V., Lotocki R.J., Unruh H.W., and Berczi I. Antiestrogens sensitize ovarian and lung carcinomas for lysis by autologous killer cells. Anticancer Res 20 (2000) 2027
53. Berczi I., Nagy E., and Baral E. The amplification of cell-mediated cytolysis by estradiol and tamoxifen. 8th International Congress of Immunology. Budapest, Hungary (August 23-28, 1992)
54. Baral E., Nagy E., Kangas L., and Berczi I. Immunotherapy of the SL2-5 murine lymphoma with natural killer cells and tamoxifen or toremifene. Anticancer Res 17 (1997) 77
55. Baral E., Nagy E., and Berczi I. Enhancement of natural killer cell mediated cytotoxicity by tamoxifen. Cancer 75 (1995) 591
56. Uslu R., Borsellino N., Frost P., Garban H., NG C.P., Mizutani Y., Belldegrun A., and Bonavida B. Chemosensitization of human prostate carcinoma cell lines to anti-Fas-mediated cytotoxicity and apoptosis. Clin Cancer Res 3 (1997) 963
57. Ramsdell F., Seaman M.S., Miller R.E., Tough T.W., Anderson M.R., and Lynch D.H. Gld/gld mice are unable to express a functional ligand for Fas. Eur J Immunol 24 (1994) 928
58. Takahashi T., Tanaka M., Brannan C.I., Jenkins N.A., Copeland N.G., Suda T., and Nagata S. Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell 76 (1994) 969
59. Munker R., Marini F., Jiong S., Savary C., Owen Schaub L., and Andeeff M. Expression of CD95 (Fas) by gene transfer does not sensitize K562 to Fas-killing. Hematol. Cell Ther 39 (1997) 75
60. Haeryfar S.M.M., Nagy E., Baral E., Krepart G., Lotocki R., and Berczi I. Antiestrogens affect both pathways of killer cell-mediated oncolysis. Anticancer Res 20 (2000) 1849
61. Uslu R., Jewett A., and Bonavida B. Sensitization of human ovarian tumor cells by subtoxic CDDP to anti-Fas antibody-mediated cytotoxicity and apoptosis. Gynecol Oncol 62 (1996) 282
62. Dotzlaw H., Leygue E., Watson P.H., and Murphy L.C. Expression of estrogen receptor-beta in human breast tumors. J Clin Endocrinol Metab (1997) 2371
63. Kroemer G. The proto-oncogene Bcl-2 and its role in regulating apoptosis. Nature Med 3 (1997) 614
64. Cheng E., Kirsch D.G., Clem R.J., Ravi R., Kastan M.B., Bedi A., Ueno K., and Hardwick J.M. Conversion of Bcl-2 to a Bax-like death effector by caspases. Science 278 (1997) 1966
65. Grandgirard D., Studer E., Monney L., Besler T., Fellay I., Borner C., and Michel M.R. Alphaviruses induced apoptosis in Bcl-2 overexpressing cells: Evidence for a caspasemediated, proteolytic inactivation of Bcl-2. EMBO J 17 (1998) 1268
66. Fujita N., and Tsuruo T. Involvment of Bcl-2 cleavage in the acceleration of VP-16-induced U937 cell apoptosis. Biochem Biophys Res Comm 246 (1998) 484
67. Chiu U.K., Walsh C.M., Liu C., Reed J.C., and Clark W.R. Bcl-2 blocks degranulation but not Fas-based cell-mediated cytotoxicity. J Immunol 154 (1995) 2023-2029
68. Berchem J.G., Bosseler M., Sugars L.Y., Voeller H.Y., Zeitlin S., and Gelmann E.P. Androgens induce resistance to Bcl-2 mediated apoptosis in LnCAP prostate cancer cells. Cancer Res 55 (1995) 735
69. Valassiadou K.E., Stefanaki K., Tzardi M., Datseris G., Georgoulias V., Melissas J., Tsiftsis D.D., Delides G., and kanavaros P. Immunohystochemical expression of p53, bcl-2, mdm2 and waf1/p21 proteins in colorectal adenocarcinomas. Anticancer Res 17 (1997) 251
70. Jonathan J., Herod O., Eliopoulos A.G., Warwick J., Niedobitek G., Young L.S., and Kerr D.J. Prognostic significance of Bcl-2 and P53 expression in ovarian carcinoma. Cancer Res 56 (1996) 2178
71. Gu W.Z., Chen Z., Tahir S.K., Rosenberg S.H., and Ng S.C. Synergistic effect of paclitaxel and 4-hydroxytamoxifen on estrogen receptor-negative colon cancer and lung cancer cell lines. Anticancer Drugs 10 (1999) 895
72. Toma S., Ugolini D., and Palumbo R. Tamoxifen in the treatment of metastatic malignant melanoma: still a controversy? (Review). Int J Oncol 15 (1999) 321